(Q50527638)

14 March 2018

title

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis (English)

1 reference

14 March 2018

0 references

1

Giancarlo Comi

1 reference

14 March 2018

5

Massimo Filippi

1 reference

14 March 2018

Douglas L Arnold

3

object named as

Douglas L Arnold

1 reference

14 March 2018

Daniel Wynn

4

object named as

Daniel Wynn

1 reference

14 March 2018

author name string

Jeffrey A Cohen

2

1 reference

14 March 2018

FORTE Study Group

6

1 reference

14 March 2018

publication date

1 January 2011

1 reference

14 March 2018

published in

Annals of Neurology

1 reference

14 March 2018

volume

69

1 reference

14 March 2018

issue

1

1 reference

14 March 2018

page(s)

75-82

1 reference

14 March 2018

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

cites work

1 reference

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

The mechanism of action of glatiramer acetate treatment in multiple sclerosis.

21 January 2018

1 reference

Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.

21 January 2018

1 reference

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis

21 January 2018

1 reference

Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.

21 January 2018

1 reference

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

21 January 2018

1 reference

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

21 January 2018

1 reference

Will Rogers phenomenon in multiple sclerosis.

21 January 2018

1 reference

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ANA.22316

1 reference

14 March 2018

1 reference

14 March 2018